[go: up one dir, main page]

MX2019003889A - Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico. - Google Patents

Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico.

Info

Publication number
MX2019003889A
MX2019003889A MX2019003889A MX2019003889A MX2019003889A MX 2019003889 A MX2019003889 A MX 2019003889A MX 2019003889 A MX2019003889 A MX 2019003889A MX 2019003889 A MX2019003889 A MX 2019003889A MX 2019003889 A MX2019003889 A MX 2019003889A
Authority
MX
Mexico
Prior art keywords
treating
preventing
fibrotic
disorder
combination compositions
Prior art date
Application number
MX2019003889A
Other languages
English (en)
Inventor
Bauer Andreas
Mueller Patrick
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2019003889A publication Critical patent/MX2019003889A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona composiciones farmacéuticas que comprenden un agonista del receptor farnesoide X (FXR) y otro agente terapéutico, en particular, para tratar o prevenir enfermedades o trastornos hepáticos.
MX2019003889A 2016-10-05 2017-10-03 Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico. MX2019003889A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662404303P 2016-10-05 2016-10-05
PCT/IB2017/056099 WO2018065902A1 (en) 2016-10-05 2017-10-03 Combination compositions comprising fxr agonists for treating or preventing a fibrotic,cirrhotic disease or disorder

Publications (1)

Publication Number Publication Date
MX2019003889A true MX2019003889A (es) 2019-08-12

Family

ID=60262958

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003889A MX2019003889A (es) 2016-10-05 2017-10-03 Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico.

Country Status (15)

Country Link
US (1) US20190231770A1 (es)
EP (1) EP3522883A1 (es)
JP (1) JP2019530696A (es)
KR (1) KR20190062501A (es)
CN (1) CN109789119A (es)
AR (1) AR109809A1 (es)
AU (1) AU2017339826A1 (es)
BR (1) BR112019005985A2 (es)
CA (1) CA3039283A1 (es)
CL (1) CL2019000914A1 (es)
IL (1) IL265817A (es)
MX (1) MX2019003889A (es)
RU (1) RU2019113150A (es)
TW (1) TW201815420A (es)
WO (1) WO2018065902A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111093705A (zh) * 2017-09-13 2020-05-01 诺华股份有限公司 包含fxr激动剂的组合
WO2020061114A1 (en) * 2018-09-18 2020-03-26 Metacrine, Inc. Farnesoid x receptor agonists for the treatment of disease
EP3999100B1 (en) * 2019-07-18 2025-08-20 ENYO Pharma Improved treatment using eyp001
WO2021053618A1 (en) * 2019-09-19 2021-03-25 Novartis Ag Treatment comprising fxr agonists
WO2021064575A1 (en) * 2019-09-30 2021-04-08 Novartis Ag Treatment comprising the use of fxr agonists
CN113244281B (zh) * 2021-06-09 2022-11-01 贵州医科大学 黄水枝醇提物在制备治疗或保护、调节肝纤维化疾病药物中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544951B2 (en) 1998-07-02 2003-04-08 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US7053056B2 (en) 1998-07-02 2006-05-30 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6197750B1 (en) 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6201118B1 (en) 1998-08-19 2001-03-13 Vertex Pharmaceuticals Inc. Process for forming an N-acylated, N,N-containing bicyclic ring from piperazic acid or an ester thereof especially useful as an intermediate in the manufacture of a caspase inhibitor
US6559304B1 (en) 1998-08-19 2003-05-06 Vertex Pharmaceuticals Incorporated Method for synthesizing caspase inhibitors
DK1163208T3 (da) 1999-08-06 2004-08-16 Vertex Pharma Caspaseinhibitorer og anvendelser deraf
US6790989B2 (en) 2000-01-13 2004-09-14 Idun Pharmaceuticals, Inc. Inhibitors of the ICE/ced-3 family of cysteine proteases
HRP20020782A2 (en) 2000-03-29 2004-12-31 Vertex Pharma Carbamate caspase inhibitors and uses thereof
US7053057B2 (en) 2000-05-23 2006-05-30 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
IL152845A0 (en) 2000-06-07 2003-06-24 Vertex Pharma Fused heterocyclic compounds and pharmaceutical compositions containing the same
PE20020500A1 (es) 2000-09-13 2002-06-25 Vertex Pharma Derivados de piperidina, tetrahidroquinolina, tetrahidroisoquinolina como inhibidores de caspasas
US6665495B1 (en) 2000-10-27 2003-12-16 Yotta Networks, Inc. Non-blocking, scalable optical router architecture and method for routing optical traffic
MXPA03009647A (es) 2001-04-19 2004-01-29 Vertex Pharma Heterociclildicarbamidas como inhibidores de caspasa.
WO2002094263A2 (en) 2001-05-23 2002-11-28 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US7410956B2 (en) 2002-02-11 2008-08-12 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
BR0312232A (pt) 2002-06-28 2005-05-10 Vertex Pharma Inibidores de caspases e seus usos
WO2004058718A1 (en) 2002-12-20 2004-07-15 Vertex Pharmaceuticals Incorporated 4-oxo-3-(1-oxo-1h-isoquinolin-2-ylacetylamino)-pentanoic acid ester and amide derivatives and their use as caspase inhibitors
PE20050159A1 (es) 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
KR100594544B1 (ko) 2003-08-27 2006-06-30 주식회사 엘지생명과학 이소옥사졸린 구조를 갖는 캐스파제 저해제
EP1718639A2 (en) 2004-02-27 2006-11-08 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
JP2005319019A (ja) 2004-05-07 2005-11-17 Bridgestone Sports Co Ltd ゴルフクラブヘッド
EP2457895A1 (en) 2004-07-12 2012-05-30 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
PL2091910T3 (pl) 2006-12-06 2015-02-27 Conatus Pharmaceuticals Inc Postacie krystaliczne kwasu (3S)-3-[N-(N’-(2-tert-butylofenylo)oksamylo)alaninylo]amino-5-(2’,3’,5’,6’-tetrafluorofenoksy)-4-oksopentanowego
WO2010120880A1 (en) * 2009-04-14 2010-10-21 Vertex Pharmaceuticals Incorporated Treatment of liver diseases with a caspase inhibitor
CU24375B1 (es) * 2013-11-05 2018-12-05 Novartis Ag Derivados de pirazol fusionados activos como moduladores del receptor de farnesoide x
US20170368038A1 (en) * 2014-12-18 2017-12-28 Novartis Ag Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
CN108697663A (zh) * 2015-12-31 2018-10-23 科内图斯医药公司 在肝病治疗中使用胱天蛋白酶抑制剂的方法
ES2862194T3 (es) * 2016-02-22 2021-10-07 Novartis Ag Métodos para usar agonistas del FXR

Also Published As

Publication number Publication date
EP3522883A1 (en) 2019-08-14
AU2017339826A1 (en) 2019-04-04
IL265817A (en) 2019-06-30
CL2019000914A1 (es) 2019-06-14
CN109789119A (zh) 2019-05-21
RU2019113150A (ru) 2020-11-06
JP2019530696A (ja) 2019-10-24
BR112019005985A2 (pt) 2019-06-25
TW201815420A (zh) 2018-05-01
WO2018065902A1 (en) 2018-04-12
CA3039283A1 (en) 2018-04-12
AR109809A1 (es) 2019-01-23
KR20190062501A (ko) 2019-06-05
US20190231770A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
MX2019003889A (es) Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico.
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
BR112016022345A2 (pt) terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40
MX2020011562A (es) Agonistas del receptor de la hormona tiroidea y usos de los mismos.
PH12018502109A1 (en) Medicine obtained by combining fxr agonist and arb
SG10201807625PA (en) Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
PH12019500326A1 (en) Combination of fxr agonists
MX382033B (es) Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
PH12018501976A1 (en) Arginase inhibitors and their therapeutic applications
MY193229A (en) Pd-l1 antagonist combination treatments
BR112016013963A2 (pt) terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
HK1252816A1 (zh) Tlr8激活剂治疗癌症的应用
MX2019014114A (es) Formulaciones para el tratamiento del trastorno de estres post-traumatico.
HK1257648A1 (zh) Fxr促效剂之使用方法
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
TW201713323A (en) Therapeutic compositions and methods of use thereof
MX2020005557A (es) Agonistas de fxr para el tratamiento de enfermedades hepaticas.
IL267716A (en) Drug combination therapies that use drugs designed for bone and bone-related diseases
MX2018006157A (es) Dispositivos y composiciones de administracion transdermica resistentes al abuso que comprenden un agonista de opioide y un derivado de n-oxido administrado por la ruta no transdermica de un antagonista de opioide para el tratamiento del dolor.